STING1 and neoplasm: Although the activation of the cGAS-STING signaling pathway has been tested as a potential cancer immunotherapy (see Therapeutic Strategies in Tumor Immunotherapy), the potential negative tumorigenic effects of overactivation of the cGAS signaling cannot be ignored.